Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines
Eli Lilly & Co. is picking up Curevo Inc., LimmaTech Biologics AG and Vaccine Company Inc. in three cash acquisitions worth as much as $3.83 billion. With the deals, the U.S. drugmaker gets its hands on vaccine programs for shingles, staph infections and Epstein-Barr virus. Lilly’s move is drawing attention as the company looks to push the surge in GLP-1 drug sales into broader growth. Mounjaro posted $8.7 billion in sales in the first quarter and Zepbound added $4.2 billion, according to Reuters last month.